文献速递糖尿病肥胖与代谢综合征

基于GLP-1的疗法对代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎的疗效:系统综述与Meta分析

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该系统综述与Meta分析纳入25项随机对照试验共2600例患者,评估GLP-1受体激动剂对MASLD/MASH的疗效。结果显示GLP-1受体激动剂治疗中位24周使肝脂肪含量降低5.21%,并显著改善肝组织学脂肪变、肝细胞气球样变和小叶内炎症,但纤维化改善无统计学意义,未观察到药物相关肝脏不良事件。

要点

  • GLP-1受体激动剂治疗中位24周使肝脂肪含量降低5.21%,其中瑞他鲁肽显示最明显疗效。
  • GLP-1受体激动剂显著改善脂肪变、肝细胞气球样变和小叶内炎症,但纤维化改善无统计学意义。
  • GLP-1受体激动剂显著降低ALT、AST和GGT,并显著改善肝硬度,未观察到药物相关肝脏不良事件。

核心结论

  • GLP-1受体激动剂减少肝脏脂肪沉积,改善组织学脂肪变、肝细胞气球样变和小叶内炎症,且未加重MASLD和MASH患者的纤维化。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Cochrane Library数据库,纳入比较GLP-1受体激动剂与安慰剂或活性药物的随机对照试验(RCTs)。
  • 共纳入25项RCTs,涉及2600例使用GLP-1受体激动剂(包括利拉鲁肽、艾塞那肽、度拉糖肽、司美格鲁肽、替尔泊肽、efinopegdutide、survodutide和瑞他鲁肽)的患者。
  • 采用随机效应模型合并均数差和风险比及其95%置信区间。

主要发现

  • GLP-1受体激动剂治疗中位24周使肝脂肪含量(LFC)显著降低5.21%,其中瑞他鲁肽显示最明显的治疗效果。
  • GLP-1受体激动剂治疗显著改善组织学脂肪变、肝细胞气球样变和小叶内炎症,但纤维化改善无统计学意义,替尔泊肽的证据比司美格鲁肽和利拉鲁肽更稳健。
  • 与对照组相比,GLP-1受体激动剂治疗显著降低血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和γ-谷氨酰转移酶(GGT)。
  • GLP-1受体激动剂还显著改善肝硬度,其中司美格鲁肽显示最明显的治疗效果。
  • 未观察到涉及肝脏的药物相关不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: New therapies are urgently needed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We conducted this systematic review and meta-analysis to evaluate the therapeutic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on MASLD/MASH. METHODS: We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH. The effects of GLP-1RAs on liver fat content (LFC) by imaging, liver histology, serum liver enzymes, and noninvasive fibrosis indexes [Fibrosis-4, nonalcoholic fatty liver disease fibrosis score, cytokeratin 18, procollagen III, and liver stiffness) were evaluated. Mean differences and risk ratios with 95% confidence intervals were pooled using a random-effect model. RESULTS: Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included. Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with retatrutide displaying the most obvious treatment effects. GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation but nonsignificantly improved fibrosis, with the evidence for tirzepatide more robust than that for semaglutide and liraglutide. GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control. GLP-1RAs also significantly improved liver stiffness, with semaglutide displaying the most obvious treatment effect. No drug-related adverse effects involving the liver were observed. CONCLUSION: GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhou Y, Wang Z, et al. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2025. PMID: 40489581. doi:10.1210/clinem/dgaf336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。